Leuven Research and Development, University of Leuven, 3000, Leuven, Belgium.
Research Institute Sant Joan de Déu, University of Barcelona, Esplugues, 08950, Barcelona, Spain.
J Endocrinol Invest. 2024 Apr;47(4):1037-1043. doi: 10.1007/s40618-023-02206-0. Epub 2023 Oct 8.
Adolescent polycystic ovary syndrome (PCOS) is characterized by androgen excess and oligo-amenorrhea, and often results from ectopic lipid storage due to a mismatch between early adipogenesis and later lipogenesis. Endogenous HOX transcript antisense RNA (HOTAIR) and exogenous pioglitazone are enhancers of subcutaneous adipogenesis, particularly in the gluteofemoral region. The A allele of HOTAIR rs1443512 is an equivalent of a natural knock-down and is, thus, a candidate to influence the distribution of fat mass, and also the redistribution of fat mass by pioglitazone in adolescent PCOS-without-obesity.
We performed two post hoc analyses by HOTAIR rs1443512 genotype. In the first, we analyzed the pooled pre-treatment data (auxology; endocrinology; body composition by dual X-ray absorptiometry; abdominal fat distribution by magnetic resonance imaging) of 65 adolescent girls with PCOS-without-obesity in three reported studies (ISRCTN45546616; ISRCTN29234515; ISRCTN11062950). In the second, we analyzed the results of 24 adolescent girls with PCOS-without-obesity, who received pioglitazone (7.5 mg/d for 1 year) as part of a randomized combination treatment (with spironolactone and metformin) in two reported studies (ISRCTN29234515; ISRCTN11062950). All data had been obtained in a blinded-to-genotype way.
The pre-treatment data disclosed that the girls-with-A-allele of HOTAIR rs1443512 had developed PCOS with a lower BMI (22.3 ± 2.3 kg/m; N = 17) than the other girls (24.1 ± 2.7 kg/m; N = 48), this difference being essentially attributable to a lower fat mass (mean difference 4.6 kg; P < 0.01). On low-dose pioglitazone, girls-with-A-allele (N = 12) raised their fat mass while the other girls (N = 12) did not (total fat mass + 2.2 ± 1.8 kg vs - 0.9 ± 2.2 kg; P < 0.001), particularly in the gynoid area (gluteofemoral fat + 0.6 ± 0.4 kg vs - 0.1 ± 0.5 kg; hip circumference + 2.3 ± 1.9 cm vs - 1.7 ± 3.1 cm; both P < 0.001).
The present findings suggest that the HOTAIR rs1443512 genotype influences not only the distribution of fat mass in adolescent girls with PCOS-without-obesity but also the redistribution of fat mass during prolonged treatment with low-dose pioglitazone.
ISRCTN45546616 ( https://doi.org/10.1186/ISRCTN45546616 ). ISRCTN29234515 ( https://doi.org/10.1186/ISRCTN29234515 ). ISRCTN11062950 ( https://doi.org/10.1186/ISRCTN11062950 ).
青少年多囊卵巢综合征(PCOS)的特征是雄激素过多和少经,通常由于早期脂肪生成和后期脂肪生成之间的不匹配而导致异位脂质储存。内源性 HOX 转录反义 RNA(HOTAIR)和外源性吡格列酮是皮下脂肪生成的增强剂,特别是在臀股区域。HOTAIR rs1443512 的 A 等位基因是一种天然敲低的等效物,因此是影响脂肪质量分布的候选物,也是吡格列酮在无肥胖青少年 PCOS 中重新分布脂肪质量的候选物。
我们通过 HOTAIR rs1443512 基因型进行了两项事后分析。在第一项分析中,我们分析了三项已发表研究(ISRCTN45546616;ISRCTN29234515;ISRCTN11062950)中 65 名无肥胖青少年 PCOS 患者的预处理数据(体格检查;内分泌学;双能 X 射线吸收法测定的身体成分;磁共振成像测定的腹部脂肪分布)。在第二项分析中,我们分析了 24 名无肥胖青少年 PCOS 患者的结果,这些患者在两项已发表的研究(ISRCTN29234515;ISRCTN11062950)中接受了吡格列酮(7.5mg/d,持续 1 年)的随机联合治疗(与螺内酯和二甲双胍联合治疗)。所有数据均以基因型盲法获得。
预处理数据显示,携带 HOTAIR rs1443512 A 等位基因的女孩(N=17)与其他女孩(N=48)相比,发生 PCOS 的 BMI 较低(22.3±2.3kg/m),这种差异主要归因于脂肪质量较低(平均差异 4.6kg;P<0.01)。在低剂量吡格列酮治疗下,携带 A 等位基因的女孩(N=12)增加了脂肪质量,而其他女孩(N=12)则没有(总脂肪质量增加 2.2±1.8kg 与减少 0.9±2.2kg;P<0.001),特别是在女性区域(臀股脂肪增加 0.6±0.4kg 与减少 0.1±0.5kg;臀围增加 2.3±1.9cm 与减少 1.7±3.1cm;均 P<0.001)。
本研究结果表明,HOTAIR rs1443512 基因型不仅影响无肥胖青少年 PCOS 患者的脂肪质量分布,还影响低剂量吡格列酮长期治疗期间脂肪质量的再分布。